SCHEMBL5137877

SCHEMBL5137877

CCCCn1c(CN(Cc2ccc3c(c2)OCO3)Cc2cc(C(F)(F)F)ccc2Cl)cnc1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.52
UBE2M P61081 4/20 0.40
DCUN1D1 Q96GG9 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.38
TDP1 Q9NUW8 1/20 0.38
KCNH2 Q12809 1/20 0.38
LMNA P02545 2/20 0.37
ALDH1A1 P00352 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
HSP90AA1 P07900 2/20 0.35
HSP90AB1 P08238 2/20 0.35
CRHR1 P34998 1/20 0.35
TRPV4 Q9HBA0 1/20 0.35
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135216 0.90 C5AR1 (0.55) C5AR1SMN1; SMN2TDP1LMNAALDH1A1
SCHEMBL5135220 0.89 C5AR1 (0.56) C5AR1SMN1; SMN2TDP1LMNAALDH1A1
SCHEMBL5135479 0.88 C5AR1 (0.55) C5AR1SMN1; SMN2TDP1LMNAALDH1A1
SCHEMBL647999 0.88 C5AR1 (0.62) C5AR1SMN1; SMN2TDP1LMNAALDH1A1
SCHEMBL5135129 0.88 C5AR1 (0.53) C5AR1UBE2MDCUN1D1SMN1; SMN2TDP1
SCHEMBL5136697 0.87 C5AR1 (0.51) C5AR1SMN1; SMN2TDP1LMNAALDH1A1
SCHEMBL5134951 0.87 C5AR1 (0.53) C5AR1UBE2MDCUN1D1SMN1; SMN2TDP1
SCHEMBL5135631 0.86 C5AR1 (0.55) C5AR1UBE2MDCUN1D1SMN1; SMN2TDP1
SCHEMBL5137416 0.86 C5AR1 (0.56) C5AR1SMN1; SMN2TDP1LMNAALDH1A1
SCHEMBL650673 0.86 C5AR1 (0.60) C5AR1UBE2MDCUN1D1SMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed